Company
About Company
Carcinotech is a MedTech company with expertise in manufacturing 3D printed living tumours using patient-derived biopsies, primary cells, immune cells and cancer stem cells. Carcinotech’s advanced models provide a platform for rapid, ethical, and accurate drug screening, pre-clinical and personalised medicine testing.
Working with global partners, leading pharma companies, surgeons, pathologists, clinicians, and industry leaders, the goal is to accelerate drug screening and enable the delivery of more effective cancer treatments to market. Access to Carcinotech’s robotic and automated manufacturing allows for accelerated production, with models offering high-throughput capabilities.
Our Carcino3D™ models offer a platform for in vitro high-throughput, accurate and rapid drug discovery and screening for novel, combinatorial and repurposed drugs. Our models can be used for drug efficacy, drug pathway, and toxicity testing. They are bioengineered to de-risk cancer drug testing and pre-clinical trials offering translational data with respect to cancer heterogeneity and microenvironments.
Press Kit
Thank you for your interest in Carcinotech. Find our brand assets below for download and use in any content regarding our brand. Please take the time to read through our branding guidelines so as to apply our materials correctly.
Media Contact
Carcinotech’s expert scientific team is available to comment on topics relating to 3D bioprinting, pre-clinical and personalised medicine testing in the oncology space. For any media and PR requests please contact stephen.mcrae@carcinotech.co.uk
Brand Assets
Our Development Process
- The current Drug Development Pipeline is inefficient. For the thousands of drugs investigated in early-stage research, only 1 is likely to make it to market.
- Carcinotech is tackling this problem by addressing some of the inefficiencies in the drug development process.
- We are developing 3D models that accurately represent the in vivo human environment. Our models are patient-specific, made from human cell lines, and contain no animal products.
- This allows a better prediction of how a drug will behave in a human body. Therefore, drugs that look promising following testing on our models are more likely to succeed in further development and clinical trials.
Carcinotech is supported by:
